about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

ARCH leads $130M in­fu­sion in­to Be Bio's long pur­suit of B cell ther­a­pies for rare dis­ease, can­cer

4 years ago
Financing
Startups

As an­titrust case wraps, Mar­tin Shkre­li's lawyers say they're owed $2M+ in un­paid le­gal fees

4 years ago
People
Law

From $3M to $1.9B: Glax­o­SmithK­line in­serts dis­card­ed Gilead drug in­to late-stage port­fo­lio, buy­ing out the turn­around ...

4 years ago
Deals

Stan­ford spin­out racks up more sup­port for its mR­NA ap­proach to cel­lu­lar re­ju­ve­na­tion

4 years ago
Financing
Startups

Thou­sands of lay­offs planned as part of No­var­tis re­struc­tur­ing — re­port

4 years ago
People
Pharma

As FDA lifts clin­i­cal hold on its $4.9B CD47 drug, Gilead talks 2023 read­out, 'un­wa­ver­ing' con­fi­dence

4 years ago
FDA+

Mer­ck ex­tends pact with NK cell spe­cial­ists at Arti­va; Re­gen­eron-al­lied biotech pen­cils in $15M IPO

4 years ago
News Briefing

Can a with­drawn Eli Lil­ly drug find sec­ond life in ra­dio­phar­ma? Lit­tle biotech hands over $5M cash to find out

4 years ago
Deals

Lat­est news on ‘dev­as­tat­ing’ Ab­b­Vie drug dis­con­tin­u­a­tion; Bio­gen's worst case sce­nario; Fi­nal­ly, some M&A; and ...

4 years ago
Weekly

Af­ter tak­ing a $73M hit, J&J part­ner Gen­mab los­es ar­bi­tra­tion over roy­al­ties on megablock­buster Darza­lex

4 years ago
Deals
Pharma

With an eye to 'non-ob­vi­ous bind­ing sites,' CBC Group launch­es pre­ci­sion med­i­cine play with $67M and ex-Ed­i­tas ex­ec ...

4 years ago
Financing
Startups

Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body

4 years ago
Deals
China

No­var­tis' PI3K drug, al­ready ap­proved in breast can­cer, nabs a speedy OK to treat ul­tra-rare con­di­tion

4 years ago
Pharma
FDA+

'S­tuck in the past': Athi­ra hits back at bil­lion­aire backer and his bid to put oust­ed CEO Leen Kawas back in the ...

4 years ago
People

PhI­Ib im­plo­sion punts Imara back to pre­clin­i­cal mode as biotech ax­es pro­grams in sick­le cell dis­ease, ...

4 years ago
R&D

Spot­light­ing sub­group analy­sis, Ther­a­vance tries to carve out 'nar­row, but crit­i­cal­ly im­por­tan­t' mar­ket for failed ...

4 years ago
R&D

'About as true as say­ing the earth is flat': Alzheimer's ex­pert picks apart Bio­gen's Aduhelm man­u­script

4 years ago
People
R&D

Af­ter steer­ing made-in-Chi­na CAR-T all the way from ob­scu­ri­ty to ap­proval, Frank Fan re­signs from Leg­end

4 years ago
People
China

Bris­tol My­ers touts up­beat da­ta for its block­buster heart drug can­di­date

4 years ago
R&D

A Penn spin­out goes dark; Thumbs down on ALS drug; TIG­IT runs in­to PhI­II flop; Sanofi's got big plans; and more

4 years ago
Weekly

In­spired by Break­ing Bad to make ricin, ex-biotech ex­ec sen­tenced for ly­ing to FBI

4 years ago
People

Af­ter an RTF and some stern warn­ings, FDA slaps Cy­to­Dyn with two clin­i­cal holds

4 years ago
FDA+

SEC to pro­pose new rules to rein in SPACs — re­port; mR­NA start­up lands $27M launch round

4 years ago
News Briefing

In a bid to push be­yond fi­nan­cial hub sta­tus, Ca­nary Wharf plots £500M wet lab build­ing

4 years ago
Pharma
First page Previous page 33343536373839 Next page Last page
A service from the Financial Times